Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 15/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5050319 | 0.92 | PTGER2 (0.62) | PTGER2 | |
| SCHEMBL5046454 | 0.92 | PTGER2 (0.55) | PTGER2 | |
| SCHEMBL13399304 | 0.92 | PTGER2 (0.51) | PTGER2 | |
| SCHEMBL5050304 | 0.90 | PTGER2 (0.52) | PTGER2 | |
| SCHEMBL5049429 | 0.88 | PTGER2 (0.55) | PTGER2 | |
| SCHEMBL5050266 | 0.87 | TAS2R14 (0.49) | PTGER2 | |
| SCHEMBL5049404 | 0.87 | PTGER2 (0.51) | PTGER2 | |
| SCHEMBL13398771 | 0.85 | CA12 (0.56) | PTGER2 | |
| SCHEMBL5049502 | 0.85 | PTGER2 (0.52) | PTGER2 | |
| SCHEMBL5046576 | 0.84 | PTGER2 (0.55) | PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045545-A1 | EP2 AGONISTS | PTGER2, PTGER1, PTGIR | PTGER2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.